TCTP

近日，一家韩国Biotech公司走入了人们的视野。8月11日，CRDMO龙头药明生物宣布与韩国生物技术公司Boostimmune签署了合作备忘录，根据已公布的信息来看，此次药明将支持Boostimmune开发不同类型的候选药物，包括单克隆抗体、双特异性抗体和重组蛋白。虽然这家仅仅成立2年的公司信息有限，但从官网仍然可以看出这家公司目前主要正在开发翻译控制肿瘤蛋白(TCTP)这一靶点的相关药物。TCTP：近年来被东大团队开发的免疫靶点从该公司提供的发表刊物来看，目前该公司的TCTP靶点的相关论文主要还是由日本东京大学团队的研发成果提供。不过，该日本团队并没有选择在本国内进行技术转化，这一点原因不得而知，可能和产业政策相关。而从其靶点具体内容来看，TCTP其实很早就被发现（40多年前），在免疫之外的功能主要在于蛋白质合成和降解的调节，生长和发育的纺锤体组装，细胞应激和自噬的调节，但在免疫方面的功能则主要是被该东京大学的团队鉴定出来的。TCTP是由坏死肿瘤细胞产生的免疫抑制成分，能够以TLR2依赖的形式来招募骨髓源性抑制细胞(MDSCs)来抑制淋巴细胞的抗肿瘤功能和向肿瘤的运输能力。而采用TCTP抗体55F3+双氢青蒿素与PD-1联用则显著加强了PD-1抗体的抗肿瘤效应。不过既然此次Boostimmune找到了药明，也可能说明当时的TCTP抗体可能仍然有完善的空间。毕竟TCTP在其他方面也有如此多的功能，筛选一款选择性的抑制抗体可能是个更好的方向。小编总结总的来说，此次药明如果在TCTP的基础上开发，是有可能去开发下一代TCTP单抗，甚至是TCTP/PD-1或TCTP/PD-L1双抗的。参考来源：Bommer UA, Telerman A. Dysregulation of TCTP in Biological Processes and Diseases. Cells. 2020 Jul 7;9(7):1632. doi: 10.3390/cells9071632.Hangai, S., Kawamura, T., Kimura, Y. et al. Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. Nat Immunol 22, 947–957 (2021). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41590-021-00967-5Jeong-Hyun Ryou, Gwanghee Lee, Tadatsugu Taniguchi, Hideyuki Yanai, Sho Hangai. TCTP is a target for cancer immunotherapy modulating myeloid-derived suppressor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 242.Ma, Y. Tpt1 the balance toward immunosuppression upon cell death. Nat Immunol 22, 940–942 (2021). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41590-021-00986-2本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处﹀ ·········点亮在看，传递信息♥

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Science2Startup (S2S) ™ , an invitation-only symposium presented by Atlas Venture , F-Prime Capital , Osage University Partners , RA Capital Management , 5AM Ventures and Massachusetts Biotechnology Council (MassBio) that aims to strengthen connections between therapeutics researchers at the world’s top academic research institutions and biotech investors, will be held May 3, 2023 at the Broad Institute in Cambridge, Massachusetts. S2S is returning for the first time since 2019, with a focus on bringing academic innovations in the therapeutics space to the attention of the thriving Boston-based venture capital ecosystem. This year’s S2S is led and organized by Kevin Bitterman, Ph.D., Partner at Atlas Venture; Jessica Alston, Ph.D., Partner at F-Prime Capital; Matt Cohen, Ph.D., Managing Partner at Osage University Partners; Joshua Resnick, M.D., Managing Director at RA Capital Management; and Jamil Beg, Partner at 5AM Ventures. The keynote address will be delivered by Sangeeta Bhatia, John J. and Dorothy Wilson Professor at MIT’s Institute for Medical Engineering and Science and Electrical Engineering and Computer Science at the Massachusetts Institute of Technology. The ten selected presenters will showcase their discoveries as well as their projected development path toward clinical proof-of-concept. Mentorship for the selected presenters, from experts across multiple disciplines, is facilitated by MassBio. S2S is generously sponsored by Deloitte , Evotec , Goodwin , Jones Lang LaSalle (JLL) , USQ , and Silicon Valley Bank (SVB) . Senior representatives from each sponsor will share their respective expertise with S2S presenters in closed-door workshops prior to the Symposium. “The S2S class of 2023 brings together an impressive group of scientists from some of the world’s top research institutions,” said Dr. Bitterman. “We’re excited to bring back this forum to provide exposure, guidance and mentorship for scientists beginning the often-challenging process of company formation, with the shared goal of increasing the odds of success as they begin the journey of translating their novel ideas into meaningful advances for patients.” “We are thrilled for S2S to return for the third year, especially following the COVID-induced hiatus,” said Dr. Alston. “Our goal is to foster collaboration among Boston’s established biotech ecosystem of investors, mentors and scientists, while also infusing the space with new ideas from entrepreneurs at leading academic institutions, all in service of advancing novel science for the benefit of patients.” Attendees at the event will include senior biopharma executives, life science-focused investors and biotech entrepreneurs. In addition to the presentations, S2S will provide substantial opportunities for networking among the presenters and attendees. “Research universities are at the forefront of pioneering innovative and novel concepts for treating human illness,” said Dr. Cohen. “S2S aims to support academic founders to increase the chance of success for those who may never have been involved in the startup world before.” “S2S aims to bring the best of what Boston has to offer to researchers from around the world,” said Dr. Resnick. “By pairing top scientists with industry mentors who can support them, we aim to both infuse the biotech economy with new ideas while also accelerating the process of therapeutic development. We are delighted to continue to support this event and look forward to seeing what this year’s S2S participants accomplish in the future.” “We are thrilled to be joining S2S this year to work with our peers in the Boston area to connect with a new generation of startups,” said Beg. “The group of scientists slated to present demonstrates a great deal of promise and we’re excited to aid in the advancement of new scientific discoveries.” This year’s ten scientific presenters were selected by an advisory group comprised of experienced biotech investors. S2S received over 125 submissions from 61 institutions across eight countries. The selected presenters are enrolled in a mentorship program led by MassBio, where they will receive one-on-one mentorship from advisory group members and other industry participants, as well as feedback on their scientific translation and drug development plans. S2S’s class of 2023 includes: Sarki Abdulkadir, M.D., Ph.D. , Co-Founder of Vortex Therapeutics, Professor of Urology and Pathology, Northwestern University. Small molecule MYC inhibitors leveraging unique insights into MYC structure and function. Thomas H. Barker, Ph.D. , Co-Founder and CSO, Vasarya Therapeutics; Professor, University of Virginia. Developing targeted treatments for fibrotic disorders. Jonathan Bernardini, Ph.D. , Postdoctoral Researcher, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. BioTACs as a next generation cell surface degrader approach. Jacqueline Burke, Ph.D. , Senior Scientist, DuPage Medical Technology, Inc.; Research Assistant Professor, University of Illinois Chicago. Novel peptide that selectively inhibits platelet and leukocyte activation and high-loading peptide nanoparticles enabling in vivo delivery for the treatment of thrombo-inflammation and ischemia-reperfusion injury. Ken Fujise, M.D. , Professor and the Harold T. Dodge-John L. Locke Chair in Cardiovascular Medicine, University of Washington. Fortilin, a macrophage (MФ) survival molecule, as a new and viable molecular target of atherosclerosis. Paraskevi (Evi) Giannakakou, Ph.D. , Professor of Pharmacology in Medicine and Associate Director of Education at the Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine. First-in-class small molecule inhibitor of androgen receptor splice variant 7, for the treatment of drug-resistant prostate cancer. Peng Ji, M.D., Ph.D. , Professor of Pathology, Northwestern University. Novel small molecule compounds targeting Pleckstrin-2, a newly discovered protein critical for the pathogenesis of myeloproliferative neoplasms. Kirill Martemyanov, Ph.D. , Co-founder, EvoDenovo; Professor and Chair, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology. New strategies for improving safety of opioid drugs and combating opioid use disorder based on innovative discovery of novel drug targets. James H. Morrissey, Ph.D. , Professor, University of Michigan Medical School . Novel platform for the reversal of all types of heparin in current clinical use. James Shayman, M.D. , Professor of Internal Medicine and Pharmacology, University of Michigan Medical School. Next generation inhibitors of glucosylceramide synthase for the treatment of neuronopathic and non-neuronopathic glycosphingolipid storage disorders. For a list of S2S’s 2023 advisors, please visit www.science2startup.com . About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com . About F-Prime Capital F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our venture capital group has had the privilege of backing great entrepreneurs building ground-breaking companies. With over $3 billion dollars under management and a global portfolio of more than 200 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech and health IT & services in a stage-agnostic fashion. Our healthcare fund has created or co-created 29 companies including Denali, Beam, Innovent, Orchard and Sana and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted and Ultragenyx. F-Prime portfolio companies have seen more than 32 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact. For more information, please visit www.fprimecapital.com . About Osage University Partners Osage University Partners (OUP) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, climate tech, and life science companies at all stages of company development. Since 2009, OUP has partnered with over 100 universities, including 27 of the top 30 U.S. institutions by research expenditures, and has invested in over 130 of their spinouts. For more information, visit oup.vc . About RA Capital Management RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit www.racap.com . About 5AM Ventures Founded in 2002, 5AM Ventures is a leading venture capital firm focused on building next-generation life science companies. Based in San Francisco and Boston, 5AM takes a hands-on approach to investing and company building, often going beyond traditional board roles to leverage our diverse team of scientists, clinicians, drug developers and executives throughout a company’s life. With over $2.2 billion raised since inception, 5AM has invested globally in over 100 public and private companies. For more information, please visit www.5amventures.com . About MassBio MassBio’s mission is to advance Massachusetts’ leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. MassBio represents the premier global life sciences and healthcare hub, with 1,600+ members dedicated to preventing, treating, and curing diseases through transformative science and technology that brings value and hope to patients. Founded in 1985, MassBio works to advance policy and promote education, while providing member programs, events, industry information, and services. For more information, visit www.massbio.org .